Literature DB >> 1606741

Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.

M B Hansen1, M Svenson, K Bendtzen.   

Abstract

IgG antibodies binding to different IFN species have been described in sera of healthy and diseased individuals. Human serum immunoglobulins have also been shown to interfere with IFN bioactivity. To characterize these antibodies, human recombinant IFN-alpha 2A (rIFN-alpha) was radioiodinated, and ligand binding studies were performed in human sera as well as on the human cell line A-549 in the presence of human serum. 125I-rIFN-alpha bound to serum factors of healthy individuals. However, less than 3% of the binding was to IgG and the binding was non-saturable and therefore most likely non-specific. 125I-rIFN-alpha bound to receptors on A-549 cells, and the ligand-receptor complexes appeared to internalize. However, both cell binding and internalization of 125I-rIFN-alpha were independent of the presence of human serum. We conclude that normal human sera do not contain detectable autoantibodies to rIFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606741      PMCID: PMC1554525          DOI: 10.1111/j.1365-2249.1992.tb06487.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Interleukin-1 receptors on human thyroid cells and on the rat thyroid cell line FRTL-5.

Authors:  M Svenson; L Kayser; M B Hansen; A K Rasmussen; K Bendtzen
Journal:  Cytokine       Date:  1991-03       Impact factor: 3.861

2.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

3.  Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.

Authors:  C Ross; M B Hansen; T Schyberg; K Berg
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

4.  Radioiodination of human alpha interferons by the chloramine T method.

Authors:  K E Mogensen; G Uzé
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Interferon receptors.

Authors:  M Aguet; K E Mogensen
Journal:  Interferon       Date:  1983

6.  Anti-interleukin-6 antibodies in normal human serum.

Authors:  M B Hansen; M Svenson; M Diamant; K Bendtzen
Journal:  Scand J Immunol       Date:  1991-06       Impact factor: 3.487

7.  Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera.

Authors:  M Svenson; M Bagge Hansen; K Bendtzen
Journal:  Scand J Immunol       Date:  1990-12       Impact factor: 3.487

8.  Human anti-interleukin 1 alpha antibodies.

Authors:  M B Hansen; M Svenson; K Bendtzen
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

9.  Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis.

Authors:  Y Ikeda; G Toda; N Hashimoto; N Umeda; K Miyake; M Yamanaka; K Kurokowa
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

10.  Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects.

Authors:  H Suzuki; T Ayabe; J Kamimura; H Kashiwagi
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

View more
  4 in total

1.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

2.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

3.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

4.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

Authors:  Juan García-Arriaza; Pilar Arnáez; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.